Business Context and Reporting Period
Company: Kimberly-Clark Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Business Overview: A global health and hygiene company operating in three reportable segments: Personal Care (e.g., Huggies, Kotex), Consumer Tissue (e.g., Kleenex, Scott), and Business-to-Business (e.g., Kimberly-Clark Professional). The company manufactures and markets products in over 150 countries.
Key Financial Metrics
| Metric (Millions, except per share) | 2005 | 2004 |
|---|---|---|
| Net Sales | $15,902.6 | $15,083.2 |
| Gross Profit | $5,075.2 | $5,068.5 |
| Operating Profit | $2,310.6 | $2,506.4 |
| Net Income | $1,568.3 | $1,800.2 |
| Diluted EPS | $3.28 | $3.61 |
| Cash Flow from Operations | $2,311.8 | $2,726.2 |
| Total Assets | $16,303.2 | $17,018.0 |
| Long-Term Debt | $2,594.7 | $2,298.0 |
| Stockholders' Equity | $5,558.2 | $6,629.5 |
Margins: Operating profit margin declined to 14.5% in 2005 from 16.6% in 2004. Gross margin remained relatively stable at approximately 32%.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 5.4% driven by a 3% volume increase and favorable currency effects (approx. 2%), partially offset by lower net selling prices in North America and Europe.
- Profit Decline: Operating profit decreased 7.8% and Net Income decreased 12.9%. This was primarily due to $228.6 million in charges related to the "Competitive Improvement Initiatives" (strategic cost reductions), cost inflation of approximately $400 million, and higher marketing expenses.
- Segment Performance:
- Personal Care: Sales up 5.2%; Operating profit down 0.9% due to material cost inflation (polymer resins, superabsorbents).
- Consumer Tissue: Sales up 8.2%; Operating profit essentially flat (+0.3%).
- Business-to-Business: Sales down 3.4% (impacted by the 2004 Neenah Paper spin-off); Operating profit up 2.5%.
- Shareholder Returns: The company returned $2.3 billion to shareholders via dividends and share repurchases. Approximately 24.3 million shares were repurchased in 2005 at a cost of $1.5 billion.
Guidance, Outlook, and Risks
Competitive Improvement Initiatives
In July 2005, the company launched a multi-year program to streamline operations and accelerate growth investments. The initiative is expected to result in cumulative pre-tax charges of $900 million to $1.1 billion through 2008, with anticipated annual pre-tax savings of $300-$350 million by 2009. This includes a net workforce reduction of approximately 6,000 employees (10%) and the closure or streamlining of 20 manufacturing facilities.
Outlook
Management expects net sales to benefit from new product introductions and growth in developing/emerging markets. The company aims to deliver sustainable growth in net income despite anticipated inflationary pressures.
Risks and Contingencies
- Commodity Prices: Significant exposure to pulp, polypropylene, and energy costs. The company does not use derivatives to manage pulp or polypropylene price risk.
- Competition: Intense pricing pressure in North America and Europe, particularly in the diaper and tissue categories.
- Legal: Ongoing asbestos litigation (claims tendered to insurance) and environmental remediation obligations. Management does not expect these to have a material adverse effect.
- Tax: Repatriation of $985 million in foreign earnings under the American Jobs Creation Act resulted in a $55.5 million tax expense in 2005.
Investor Verification Checklist
- Cost Inflation Impact: Verify the ability to pass on raw material (pulp, oil-based) cost increases to consumers without losing market share.
- Initiative Execution: Monitor the realization of the projected $300-$350 million annual savings from the Competitive Improvement Initiatives against the $900M-$1.1B in charges.
- European Performance: Assess the turnaround strategy in Europe, which faced significant sales declines and operating profit pressure in 2005.
- Pension Obligations: Review the funded status of defined benefit plans, which showed a projected benefit obligation exceeding plan assets by approximately $1.4 billion.
- Share Repurchase Program: Confirm the remaining capacity under the authorized share repurchase programs ($5.0 billion authorization).